Opioid-Related Disorders Clinical Trial
Official title:
Time to Detox: A Patient-Centered Comparison of Length of Detoxification Treatment and Time to Naltrexone Maintenance Therapy in Opioid-Dependent Individuals
Despite an increased focus on treating opioid use disorder there are relatively few studies that compare the length of time required for detoxification with medications other than buprenorphine. Morphine and tramadol have shorter half-lives than buprenorphine and can be used for opioid detoxification. The proposed protocol aims to address this gap by directly comparing the length of treatment required for detoxification from opioids in a patient-centered manner with oral morphine, tramadol, or buprenorphine-naloxone as well as comparing the severity of withdrawal experienced by patients in each group. The investigators predict that treatment with oral morphine or tramadol will result in a faster completion of detoxification and initiation of naltrexone maintenance.
Opioid dependent individuals will be recruited for participation in the study. Upon
recruitment into the randomized trial each participant will be started on an induction dosage
of medication intended to suppress withdrawal (either buprenorphine-naloxone, morphine, or
tramadol). Participants will remain on the induction dose for at least 24 hrs. Severity of
withdrawal will be assessed twice a day using the Clinical Opiate Withdrawal Scale (COWS) and
the Subjective Opiate Withdrawal Scale (SOWS). Each morning, participants will be given the
option to progress on the tapering protocol (see below for individual regimens). Time to
complete detoxification and initiation of naltrexone treatment will be measured. At
completion of the study each participant will complete a 7-iten Detoxification Treatment
Satisfaction questionnaire.
Taper Schedule Dosing Buprenorphine-Naloxone (Suboxone): Patients will get 4mg when
withdrawal symptoms start. Patients can receive the first 8mg dose as early as 6hrs later,
and at that point will start on an 8mg twice-a-day schedule. Each morning the patient will be
assessed regarding their ability to progress to the next stage of the taper.
Buprenorphine-naloxone will be tapered 2mg/day.
Tramadol: At enrollment the patients will receive a 100mg dose and can receive another 100mg
every 6 hrs for 24 hrs. Each morning the patient will be assessed regarding their ability to
progress to the next stage of the taper. Patients will then be tapered on the following
schedule 100mg every 8 hrs, 50mg every 6 hrs, 50mg every 8 hrs, 50mg ever 12 hrs, and one
final daily dose of 50mg.
Morphine: Patients receive 30mg every 4 hours for 24 hrs from when withdrawal symptoms start.
Each morning the patient will be assessed regarding their ability to progress to the next
stage of the taper. Patients will then be tapered on the following schedule: 30 mg every 6
hours, 30 mg every 8 hours, 30 mg every 12 hours, and one final daily 30 mg dose.
As Needed Medications: Patients in all groups will have access to the following medications
as needed gabapentin 400mg every 8 hrs, loperamide 2mg every 3 hrs, odansetron 4mg every 6
hrs, ibuprofen 600mg ever 8 hrs, and hydroxyzine 25-50mg nightly.
Naltrexone Test Dose Patients will receive an oral test dose of naltrexone (25mg) either 10
days after completing the buprenorphine-naloxone taper (standard of care) or 7 days after the
morphine or tramadol taper. If the oral test dose is tolerated then the patients may choose
to pursue treatment with an extended release naltrexone intramuscular injection (380mg) 24
hrs later. Due to the risk for hepatocellular injury with naltrexone, patients with baseline
elevations in either aspartate transaminase or alanine transaminase greater than three times
the upper limit of our clinical laboratory's reference range will be ineligible to receive
extended release naltrexone, but may choose to continue oral naltrexone maintenance therapy
(50mg daily) (standard of care). As part of the study the investigators will record the time
to naltrexone maintenance therapy.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03950492 -
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
|
N/A | |
Completed |
NCT00000335 -
Activity Monitoring Assessment of Opiate Withdrawal - 4
|
Phase 2 | |
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Enrolling by invitation |
NCT06084221 -
Fatal Overdose Review Teams - Research to Enhance Surveillance Systems
|
N/A | |
Completed |
NCT02978417 -
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
|
Phase 4 | |
Withdrawn |
NCT03137030 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults
|
Phase 1 | |
Withdrawn |
NCT03137017 -
A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults
|
Phase 1 | |
Completed |
NCT02282306 -
Phone Interview to Prevent Recurring Opioid Overdoses
|
N/A | |
Completed |
NCT00710385 -
Abuse Liability of Suboxone Versus Subutex
|
Phase 3 | |
Completed |
NCT00142935 -
Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
|
N/A | |
Completed |
NCT00218309 -
Effects of Pre-Session Supplemental Hydromorphone on Drug Seeking Behavior in Opioid Dependent Individuals
|
Phase 2 | |
Terminated |
NCT00000243 -
Effects of Buprenorphine/Naloxone in Treating Opioid Dependent Individuals Who Are Maintained on Methadone
|
N/A | |
Completed |
NCT00067184 -
Fetal Neurobehavioral Development in Methadone Maintained Pregnancies
|
||
Completed |
NCT00000264 -
Subjective/Psychomotor/ Effects of Combined Alcohol & Nitrous Oxide - 16
|
N/A | |
Completed |
NCT00000257 -
Effects of Alcohol History on Effects of Nitrous Oxide - 9
|
N/A | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000279 -
Novel Medications for Opiate Detoxification - 4
|
Phase 2 | |
Completed |
NCT00000249 -
Effects of Subanesthetic Concentrations of Nitrous Oxide - 1
|
Phase 2 | |
Recruiting |
NCT04933084 -
Pre-operative Education Modalities to Decrease Opioid Use
|
N/A | |
Recruiting |
NCT03610672 -
Mobile Intervention for Young Opioid Users
|
N/A |